Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2018, Article ID 3040346, 8 pages
https://doi.org/10.1155/2018/3040346
Research Article

Serum Hepcidin Level as a Marker of Iron Status in Children with Cystic Fibrosis

1Department of Paediatrics, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
2Department of Nursing and Emergency Medicine, Faculty of Health Sciences, University of Bielsko-Biała, Bielsko-Biała, Poland

Correspondence should be addressed to Monika Kałużna-Czyż; lp.fargotua@anzulakakinom

Received 12 March 2018; Revised 23 May 2018; Accepted 28 May 2018; Published 2 July 2018

Academic Editor: Ariadne Malamitsi-Puchner

Copyright © 2018 Monika Kałużna-Czyż et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, “Assessing the iron status of populations,” 2007, http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/9789241596107/en/.
  2. L. Uijterschout, M. Nuijsink, D. Hendriks, R. Vos, and F. Brus, “Iron deficiency occurs frequently in children with cystic fibrosis,” Pediatric Pulmonology, vol. 49, no. 5, pp. 458–462, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. N. Pond, A. M. Morton, and S. P. Conway, “Functional iron deficiency in adults with cystic fibrosis,” Respiratory Medicine, vol. 90, no. 7, pp. 409–413, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. J. L. Ater, J. J. Herbst, S. A. Landaw, and R. T. O'Brien, “Relative anemia and iron deficiency in cystic fibrosis,” Pediatrics, vol. 71, no. 5, pp. 810–814, 1983. View at Google Scholar
  5. S. F. Cucchiara, F. Santamaria, M. R. Andreotti et al., “Mechanisms of gastro-oesophageal reflux in cystic fibrosis,” Archives of Disease in Childhood, vol. 66, no. 5, pp. 617–622, 1991. View at Publisher · View at Google Scholar · View at Scopus
  6. W. T. Zempsky, B. J. Rosenstein, J. A. Carroll, and F. A. Oski, “Effect of pancreatic enzyme supplements on iron absorption,” American Journal of Diseases of Children, vol. 143, no. 8, pp. 969–972, 1989. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Ehrhardt, M. G. Miller, and J. M. Littlewood, “Iron deficiency in cystic fibrosis,” Archives of Disease in Childhood, vol. 62, no. 2, pp. 185–187, 1987. View at Publisher · View at Google Scholar · View at Scopus
  8. A. H. Gifford, S. D. Miller, B. P. Jackson et al., “Iron and CF-related anemia: expanding clinical and biochemical relationships,” Pediatric Pulmonology, vol. 46, no. 2, pp. 160–165, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. Smith, G. J. Anderson, I. L. Lamont, P. Masel, S. C. Bell, and D. W. Reid, “Accurate assessment of systemic iron status in cystic fibrosis will avoid the hazards of inappropriate iron supplementation,” Journal of Cystic Fibrosis, vol. 12, no. 3, pp. 303-304, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. B. S. Skikne, K. Punnonen, P. H. Caldron et al., “Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index,” American Journal of Hematology, vol. 86, no. 11, pp. 923–927, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Uijterschout, D. W. Swinkels, M. D. Akkermans et al., “The value of soluble transferrin receptor and hepcidin in the assessment of iron status in children with cystic fibrosis,” Journal of Cystic Fibrosis, vol. 13, no. 6, pp. 639–644, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Krause, S. Neitz, H. J. Mägert et al., “LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity,” FEBS Letters, vol. 480, no. 2-3, pp. 147–150, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Nemeth, E. V. Valore, M. Territo, G. Schiller, A. Lichtenstein, and T. Ganz, “Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein,” Blood, vol. 101, no. 7, pp. 2461–2463, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. J. G. Bode, U. Albrecht, D. Häussinger, P. C. Heinrich, and F. Schaper, “Hepatic acute phase proteins—regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling,” European Journal of Cell Biology, vol. 91, no. 6-7, pp. 496–505, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Kali, M. V. P. Charles, and R. S. K. Seetharam, “Hepcidin - a novel biomarker with changing trends,” Pharmacognosy Reviews, vol. 9, no. 17, pp. 35–40, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Ruchala and E. Nemeth, “The pathophysiology and pharmacology of hepcidin,” Trends in Pharmacological Sciences, vol. 35, no. 3, pp. 155–161, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. Q. de Mast, B. Nadjm, H. Reyburn et al., “Assessment of urinary concentrations of hepcidin provides novel insight into disturbances in iron homeostasis during malarial infection,” The Journal of Infectious Diseases, vol. 199, no. 2, pp. 253–262, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. H. Gifford, L. A. Moulton, D. B. Dorman et al., “Iron homeostasis during cystic fibrosis pulmonary exacerbation,” Clinical and Translational Science, vol. 3, no. 3, pp. 368–373, 2012. View at Google Scholar
  19. A. H. Gifford, D. M. Alexandru, Z. Li et al., “Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis,” Journal of Cystic Fibrosis, vol. 13, no. 3, pp. 311–318, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Uijterschout, D. W. Swinkels, M. Domellöf et al., “Serum hepcidin measured by immunochemical and mass-spectrometric methods and their correlation with iron status indicators in healthy children aged 0.5–3 y,” Pediatric Research, vol. 76, no. 4, pp. 409–414, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. WHO, “Iron deficiency anemia assessment, prevention, and control,” 2001, http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf.
  22. T. E. Galesloot, S. H. Vermeulen, A. J. Geurts-Moespot et al., “Serum hepcidin: reference ranges and biochemical correlates in the general population,” Blood, vol. 117, no. 25, pp. e218–e225, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Ganz, G. Olbina, D. Girelli, E. Nemeth, and M. Westerman, “Immunoassay for human serum hepcidin,” Blood, vol. 112, no. 10, pp. 4292–4297, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. J. C. Kroot, C. M. M. Laarakkers, A. J. Geurts-Moespot et al., “Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders,” Clinical Chemistry, vol. 56, no. 10, pp. 1570–1579, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Cangemi, A. Pistorio, M. Miano et al., “Diagnostic potential of hepcidin testing in pediatrics,” European Journal of Haematology, vol. 90, no. 4, pp. 323–330, 2013. View at Publisher · View at Google Scholar · View at Scopus